Published in Med Klin (Munich) on June 01, 2010
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.59
Mitochondrial gene polymorphisms that protect mice from colitis. Gastroenterology (2013) 1.53
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun (2007) 1.48
The expression patterns of peritoneal defensins. Perit Dial Int (2007) 1.39
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation (2008) 1.30
Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.27
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol (2004) 1.26
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol (2006) 1.21
Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol (2007) 1.14
Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut (2007) 1.11
A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods (2005) 1.05
Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes Infect (2009) 1.03
Crohn's disease--defect in innate defence. World J Gastroenterol (2008) 0.97
The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol (2010) 0.96
Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis (2012) 0.90
Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol (2013) 0.88
A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. BMC Cancer (2012) 0.87
Human defensins in Crohn's disease. Chem Immunol Allergy (2005) 0.86
Fatal staphylococcal sepsis in Crohn's disease after infliximab. Inflamm Bowel Dis (2004) 0.85
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis (2004) 0.85
Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections. J Crohns Colitis (2007) 0.83
Crohn's targeted therapy: myth or real goal? Curr Drug Discov Technol (2009) 0.82
Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease. Inflamm Bowel Dis (2005) 0.80
Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflamm Bowel Dis (2004) 0.78
Antimicrobial peptides in the skin. N Engl J Med (2003) 0.78
Does etiology of acute pancreatitis matter? A review of 391 consecutive episodes. JOP (2015) 0.77
Colorectal neoplasia in IBD--a single-center analysis of patients undergoing proctocolectomy. Int J Colorectal Dis (2015) 0.76
Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection. PLoS One (2013) 0.76
Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment. Eur J Gastroenterol Hepatol (2015) 0.75
[Not Available]. Med Klin (Munich) (2010) 0.75
6-thioguanine-buried alive? Gastroenterology (2004) 0.75
[Not Available]. Med Klin (Munich) (2010) 0.75
Cyclophosphamide therapy in Sweet's syndrome complicating refractory Crohn's disease − Efficacy and mechanism of action. J Crohns Colitis (2011) 0.75
Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther (2014) 0.75